The UK’s medicines regulator has issued updated safety guidance on semaglutide, the widely used drug sold under brand names including Ozempic, Rybelsus and Wegovy, following new evidence about a very rare risk of sudden vision loss.
The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed on 5 February 2026 that product information for both healthcare professionals and patients has been updated to reflect the potential risk of non-arteritic anterior ischaemic optic neuropathy, known as NAION. The condition is extremely rare, but the agency says awareness is essential to protect patients.
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. It is commonly prescribed to manage type 2 diabetes and, under the Wegovy brand, to support weight loss and reduce cardiovascular risk in people who are higher weight. Its popularity has grown rapidly in the UK and among diaspora communities, where diabetes and weight-related conditions are often more prevalent.
NAION occurs when blood flow to the front part of the optic nerve is reduced. It usually presents as sudden, painless loss of vision in one eye, often described by patients as blurring or cloudiness. While the condition is rare, the MHRA is urging anyone taking semaglutide to take changes in eyesight seriously.
Patients who notice sudden visual impairment, or whose eyesight worsens quickly in one or both eyes, are advised to seek urgent medical attention by attending eye casualty services where available or going straight to A&E.
Dr Alison Cave, the MHRA’s Chief Safety Officer, said patient safety remains the regulator’s highest priority. She stressed that although the potential risk is extremely small, recognising symptoms early is vital. She also encouraged patients and carers to report suspected side effects through the MHRA’s Yellow Card scheme, which plays a key role in monitoring medicine safety across the UK.
Data reviewed by the MHRA suggests that NAION may affect up to one in 10,000 people taking semaglutide. Since the medicine was first authorised in the UK in 2018, and up to 1 August 2025, the Yellow Card system has received three reports suggestive of NAION linked to semaglutide. Over the same period, an estimated 10.2 million packs of the medicine were dispensed nationwide, highlighting just how rare the reports are.
The MHRA has also confirmed it is reviewing evidence to determine whether there is any similar association with other GLP-1 medicines.
For many people in the UK and across the diaspora, semaglutide has been life-changing, helping to manage chronic conditions that disproportionately affect Black, African and other minority ethnic communities. Health experts stress that patients should not stop taking prescribed medication without medical advice, but should stay informed and alert to any unusual symptoms.
The regulator has published a formal Drug Safety Update for healthcare professionals and continues to provide detailed guidance on the safe and effective use of semaglutide. Anyone experiencing or suspecting a side effect from any medicine can report it online via the Yellow Card website or through the MHRA Yellow Card app available on Apple and Google Play stores.
As conversations around weight loss drugs and diabetes treatments continue to grow, particularly on social media, the MHRA’s update is a reminder of the importance of trusted information, medical supervision and prompt action when something does not feel right.
Chijos News will continue to track health developments that matter to diaspora families, keeping communities informed, empowered and safe in an increasingly complex healthcare landscape.
